ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: US04272N1028
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Cellid Co., Ltd. Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.	South Korea	299660
Cellromax Science Co., Ltd. Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.	South Korea	471820
CellSeed Inc. Develops cell sheet products, culture equipment, and offers contract manufacturing services.	Japan	7776
CellSource Co.,Ltd. Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.	Japan	4880
Celltrion, Inc. A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.	South Korea	068270
Celon Pharma S.A. Researches, develops, and markets innovative drugs for oncology and neurology.	Poland	CLN
CEL SCI CORP Develops immunotherapies for cancer, autoimmune, and infectious diseases.	United States of America	CVM
Celularity Inc Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.	United States of America	CELU
Centessa Pharmaceuticals plc Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.	United States of America	CNTA
CERO THERAPEUTICS HOLDINGS, INC. Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.	United States of America	CERO